Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
Perspective Therapeutics (NYSE AMERICAN: CATX), a pioneering radiopharmaceutical company, has announced its participation in two upcoming investor conferences in August 2024. The company's senior leadership team will be available for one-on-one meetings with investors at both events.
The first conference is the BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024, which will be held virtually. The second is the 2024 Wedbush PacGrow Healthcare Conference, taking place in-person in New York, NY on August 13-14, 2024.
At the Wedbush conference, Perspective Therapeutics will also participate in a panel discussion titled 'Nuke 'em From Orbit: Radiotherapy' at 9:30am ET. This engagement highlights the company's focus on advanced treatment applications for cancers throughout the body using radiopharmaceuticals.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda pionieristica nel settore delle radioterapie, ha annunciato la sua partecipazione a due conferenze per investitori in programma per agosto 2024. Il team dirigenziale senior dell'azienda sarà disponibile per incontri privati con gli investitori durante entrambi gli eventi.
La prima conferenza è il BTIG Virtual Biotechnology Conference, previsto per il 5-6 agosto 2024, che si svolgerà virtualmente. La seconda è la 2024 Wedbush PacGrow Healthcare Conference, che si terrà in presenza a New York, NY, il 13-14 agosto 2024.
Durante la conferenza Wedbush, Perspective Therapeutics parteciperà anche a una tavola rotonda intitolata 'Nuke 'em From Orbit: Radioterapia' alle 9:30 ET. Questo impegno sottolinea l'attenzione dell'azienda sulle applicazioni terapeutiche avanzate per i tumori in tutto il corpo utilizzando radioterapie.
Perspective Therapeutics (NYSE AMERICAN: CATX), una empresa pionera en el campo de los radiofármacos, ha anunciado su participación en dos próximas conferencias para inversores en agosto de 2024. El equipo de liderazgo senior de la empresa estará disponible para reuniones uno a uno con inversores en ambos eventos.
La primera conferencia es la BTIG Virtual Biotechnology Conference, programada para el 5 y 6 de agosto de 2024, que se llevará a cabo de forma virtual. La segunda es la 2024 Wedbush PacGrow Healthcare Conference, que tendrá lugar en persona en Nueva York, NY, del 13 al 14 de agosto de 2024.
En la conferencia Wedbush, Perspective Therapeutics también participará en una mesa redonda titulada 'Nuke 'em From Orbit: Radioterapia' a las 9:30 AM ET. Esta participación resalta el enfoque de la empresa en aplicaciones de tratamiento avanzadas para cánceres en todo el cuerpo usando radiofármacos.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 선도적인 방사성 약물 회사로, 2024년 8월에 열리는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 고위 경영진 팀은 두 행사에서 투자자와 개별 미팅을 진행할 예정입니다.
첫 번째 회의는 2024년 8월 5-6일 개최되는 BTIG 가상 생명공학 컨퍼런스입니다. 두 번째는 2024년 8월 13-14일, 뉴욕 NY에서 대면으로 진행되는 Wedbush PacGrow 헬스케어 회의입니다.
Wedbush 회의에서 Perspective Therapeutics는 오전 9:30 ET에 'Nuke 'em From Orbit: 방사선 치료'라는 제목의 패널 토론에도 참여할 것입니다. 이 참여는 방사성 약물을 사용하여 신체 전반에 걸쳐 암에 대한 고급 치료 방법에 대한 회사의 집중도를 강조합니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise pionnière dans le domaine des radiopharmaceutiques, a annoncé sa participation à deux prochaines conférences pour investisseurs en août 2024. L'équipe de direction senior de l'entreprise sera disponible pour des réunions individuelles avec des investisseurs lors des deux événements.
La première conférence est la BTIG Virtual Biotechnology Conference, prévue pour les 5 et 6 août 2024, qui se tiendra virtuellement. La seconde est la 2024 Wedbush PacGrow Healthcare Conference, qui aura lieu en personne à New York, NY, les 13 et 14 août 2024.
Lors de la conférence Wedbush, Perspective Therapeutics participera également à une discussion en panel intitulée 'Nuke 'em From Orbit: Radiothérapie' à 9h30 ET. Cet engagement souligne l'accent mis par l'entreprise sur les applications de traitement avancées pour les cancers dans tout le corps utilisant des radiopharmaceutiques.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Pionierunternehmen im Bereich der Radiopharmazeutika, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im August 2024 bekannt gegeben. Das Führungsteam des Unternehmens steht bei beiden Veranstaltungen für Einzelgespräche mit Investoren zur Verfügung.
Die erste Konferenz ist die BTIG Virtual Biotechnology Conference, die am 5. und 6. August 2024 virtuell stattfinden wird. Die zweite Konferenz ist die 2024 Wedbush PacGrow Healthcare Conference, die am 13. und 14. August 2024 persönlich in New York, NY, stattfinden wird.
Während der Wedbush-Konferenz wird Perspective Therapeutics auch an einer Podiumsdiskussion mit dem Titel 'Nuke 'em From Orbit: Radiotherapie' um 9:30 Uhr ET teilnehmen. Dieses Engagement hebt den Fokus des Unternehmens auf fortschrittliche Behandlungsmöglichkeiten für Krebserkrankungen im gesamten Körper unter Verwendung von Radiopharmazeutika hervor.
- None.
- None.
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.
BTIG Virtual Biotechnology Conference 2024
Date: August 5-6, 2024
Location: Virtual
2024 Wedbush PacGrow Healthcare Conference
Date: August 13-14, 2024
Location: New York, NY (in-person only)
Panel Discussion - Nuke ‘em From Orbit: Radiotherapy
Time: 9:30am ET
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
FAQ
What investor conferences will Perspective Therapeutics (CATX) attend in August 2024?
Will Perspective Therapeutics (CATX) present at the Wedbush PacGrow Healthcare Conference?
Is the BTIG Virtual Biotechnology Conference 2024 an in-person event for Perspective Therapeutics (CATX)?
What type of meetings will Perspective Therapeutics (CATX) offer at the August 2024 investor conferences?
